[A16-69] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2017
Project no.:
A16-69
Commission:
Commission awarded on 01.11.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-85 | Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-56 | Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-10 | Cabozantinib (renal cell carcinoma) - Addendum to Commission A16-69 | Commission completed |
| G14-07 | Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| G21-20 | Cabozantinib (thyroid carcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision) | Commission completed |
| A22-59 | Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-04-20 A G-BA decision was published.